Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

• ClinicalTrials.gov Identifier: NCT02651428
• Recruitment Status: Completed
• First Posted: January 11, 2016
• Results First Posted: August 31, 2021
• Last Update Posted: August 31, 2021
• Sponsor: CorMedix
• Collaborators: PPD; JMI Laboratories; Spectra Clinical Research; Davita Clinical Research; Frenova Renal Research
• Information provided by (Responsible Party): CorMedix

Study Description

Brief Summary:

The purpose of this study is determine safety and effectiveness of Neutrolin, a catheter lock solution, for prevention of central venous catheter associated bloodstream infection in hemodialysis patients.

Condition or disease	Intervention/treatment	Phase
Kidney Failure, Chronic; Catheter-Related Infections	Drug: Neutrolin; Drug: Heparin	Phase 3

Detailed Description:

The objective of this study is to demonstrate the efficacy and safety of Neutrolin® as a catheter lock solution (CLS) on prevention of catheter-related bloodstream infection (CRBSI), and the incidence of treatment-emergent adverse events in subjects receiving hemodialysis (HD) for the treatment of End Stage Renal Disease (ESRD) when compared with heparin 4,000 USP Units/4mL (1,000 USP Units/mL).

This is a randomized, double-blind, active control, parallel-arm, multicenter study. Six hundred and thirty two subjects will be randomized in a 1:1 ratio to receive either Neutrolin® or the active control heparin (Heparin sodium USP 1,000 units/mL, Benzyl alcohol 9.45 mg/mL and Sodium chloride 9.0 mg/mL) as a CLS.

Approximately 632 randomized subjects are planned for this trial. In this study, one-half of the subjects (316 subjects) will receive Neutrolin as a study drug and the other half will receive heparin 4,000 USP Units/4mL (1,000 USP Units/mL) with benzyl alcohol preservative as a comparator. Subjects will be assigned in a 1:1 ratio using permuted blocks without additional stratification for both groups.

The primary objective of this study is to demonstrate the effectiveness of Neutrolin® as a CLS in ESRD subjects undergoing HD treatment using a permanent, cuffed, tunneled silicone or polyurethane HD catheter. The study will evaluate whether Neutrolin® is superior to the active control heparin by documenting the time to CRBSI and consequently delaying the time until the occurrence of CRBSI.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 806 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Prevention
• Official Title: Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease
• Study Start Date: December 2015
• Actual Primary Completion Date: October 2018
• Actual Study Completion Date: October 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Neutrolin arm; Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution	Drug: Neutrolin; Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session; Other Name: 1.35% taurolidine, 3.5% citrate, heparin 1,000 USP Units/mL
Active Comparator: Heparin arm; Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution	Drug: Heparin; Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session; Other Name: Heparin Sodium

Outcome Measures

Primary Outcome Measures :

1. Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis [ Time Frame: The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days). ]
   CRBSI was defined as the same organism grown from at least one positive blood culture from a peripheral site or bloodline sample, or either the arterial or venous catheter hub. The final assessment of CRBSI was determined by a Clinical Adjudication Committee (CAC) who used both clinical documentation and blood culture results in their assessment.

Secondary Outcome Measures :

1. Participants With a Study Catheter Removal for Any Reason [ Time Frame: The event time was the number of days from randomization until catheter removal for any reason or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days). ]
   Analysis of all catheter removals during the study or until the catheter was removed

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subject has ESRD and undergoes chronic HD at least two times per week
2. Subject has a HD catheter that has demonstrated the ability to achieve a minimum blood flow of at least 250 mL/min for at least two consecutive dialysis sessions blood flow to enable successful HD
3. The HD catheter is implanted with the tip in a jugular or subclavian vein
4. The subject is not expected to expire within 180 days
5. The subject is likely to require the use of a CVC for at least 90 days
6. The subject (or the legal guardian) understands the nature of the study and provides written informed consent prior to the study enrollment
7. The subject is willing to comply with specified follow-up evaluations and prescribed dialysis therapy and
8. If female and of childbearing potential, the subject must have a negative pregnancy test at the screening visit (i.e., subject is not pregnant); not be lactating; and use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the study. (NOTE: The subject must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).

Exclusion Criteria:

1. Subjects who received antibiotics within the last 14 days
2. Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection
3. Subject has received any thrombolytic treatment (i.e., tPA) in their current catheter within 30 days of randomization
4. Fill volume of HD catheter is unknown or cannot be determined
5. Subjects using any type of antimicrobial-coated or heparin-coated catheter
6. Documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization
7. Documented history of an atrial thrombus or known hypercoagulable state
8. Subjects with open, non-healing skin ulcers
9. Current requirement for systemic immunosuppression that would increase risk of infection
10. Active malignancy requiring or anticipated to require chemotherapy likely to cause leukopenia and/or immunosuppression
11. Known allergy or absolute contraindication to citrate, taurolidine or heparin or a history of heparin-induced thrombocytopenia
12. Unstable malignancy
13. Cirrhosis with encephalopathy
14. Subject is currently taking another medication with known systemic drug interaction with citrate, taurolidine, or heparin
15. Subject is currently enrolled in another investigational device and/or drug trial or has participated in another investigational device and/or drug trial within 30 days prior to enrollment
16. Subject is anticipated to receive a renal transplant within 90 days (subjects can be on the transplant list, but a subject with a known or anticipated transplant date within the next 90 days should be excluded)

17. Any other medical condition which renders the subject unable to or unlikely to complete the study, or which would interfere with optimal participation in the study or produce significant risk to the subject.

    -

Contacts and Locations

Locations

United States, California

Riverside Nephrology Physicians/Van Buren Dialysis center

Riverside, California, United States, 92503

North America Research Institute

San Dimas, California, United States, 91773

United States, Florida

North Beach Dialysis Center Inc.

Miami Gardens, Florida, United States, 33169

United States, New York

Lower Manhattan Dialysis Center

New York, New York, United States, 10016

United States, Texas

Diagnostic Clinic of Houston

Houston, Texas, United States, 77004

Sponsors and Collaborators

CorMedix

PPD

JMI Laboratories

Spectra Clinical Research

Davita Clinical Research

Frenova Renal Research

Investigators

• Study Director: Antony Pfaffle, MD; Chief Scientific Officer

  Study Documents (Full-Text)

Documents provided by CorMedix:

Study Protocol  [PDF] October 6, 2017

Statistical Analysis Plan  [PDF] January 29, 2018

More Information

• Responsible Party: CorMedix
• ClinicalTrials.gov Identifier: NCT02651428
• Other Study ID Numbers: LOCK-IT-100
• First Posted: January 11, 2016
• Results First Posted: August 31, 2021
• Last Update Posted: August 31, 2021
• Last Verified: August 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by CorMedix:

Kidney Failure, Chronic; Catheter-Related Infections; Central Venous Catheter

Additional relevant MeSH terms:

Infections; Communicable Diseases; Sepsis; Catheter-Related Infections; Renal Insufficiency; Kidney Failure, Chronic; Disease Attributes; Pathologic Processes; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Systemic Inflammatory Response Syndrome; Inflammation; Renal Insufficiency, Chronic; Chronic Disease; Taurolidine; Heparin; Calcium heparin; Anticoagulants; Molecular Mechanisms of Pharmacological Action; Fibrinolytic Agents; Fibrin Modulating Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Antineoplastic Agents